Hartmann Oliver, Reissland Michaela, Maier Carina R, Fischer Thomas, Prieto-Garcia Cristian, Baluapuri Apoorva, Schwarz Jessica, Schmitz Werner, Garrido-Rodriguez Martin, Pahor Nikolett, Davies Clare C, Bassermann Florian, Orian Amir, Wolf Elmar, Schulze Almut, Calzado Marco A, Rosenfeldt Mathias T, Diefenbacher Markus E
Deregulated Protein Stability and Cancer Laboratory, Lehrstuhl für Biochemie und Molekularbiologie, Biozentrum, Universität Würzburg, Würzburg, Germany.
Mildred Scheel Early Career Center, Würzburg, Germany.
Front Cell Dev Biol. 2021 Mar 2;9:641618. doi: 10.3389/fcell.2021.641618. eCollection 2021.
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival rate for non-small cell lung cancer (NSCLC) patients remains low, demonstrating the necessity for novel treatments. One strategy to improve translational research is the development of surrogate models reflecting somatic mutations identified in lung cancer patients as these impact treatment responses. With the advent of CRISPR-mediated genome editing, gene deletion as well as site-directed integration of point mutations enabled us to model human malignancies in more detail than ever before. Here, we report that by using CRISPR/Cas9-mediated targeting of and , we recapitulated the classic murine NSCLC model . Developing tumors were indistinguishable from -derived tumors with regard to morphology, marker expression, and transcriptional profiles. We demonstrate the applicability of CRISPR for tumor modeling and ameliorating the need to use conventional genetically engineered mouse models. Furthermore, tumor onset was not only achieved in constitutive expression but also in wild-type animals infection of lung epithelial cells with two discrete AAVs encoding different parts of the CRISPR machinery. While conventional mouse models require extensive husbandry to integrate new genetic features allowing for gene targeting, basic molecular methods suffice to inflict the desired genetic alterations . Utilizing the CRISPR toolbox, cancer research and modeling is rapidly evolving and enables researchers to swiftly develop new, clinically relevant surrogate models for translational research.
肺癌是全球最常见的癌症,也是男性和女性癌症相关死亡的主要原因。尽管新型治疗干预措施不断发展,但非小细胞肺癌(NSCLC)患者的5年生存率仍然很低,这表明需要新的治疗方法。改善转化研究的一种策略是开发反映肺癌患者体细胞突变的替代模型,因为这些突变会影响治疗反应。随着CRISPR介导的基因组编辑技术的出现,基因缺失以及点突变的定点整合使我们能够比以往更详细地模拟人类恶性肿瘤。在此,我们报告通过使用CRISPR/Cas9介导的对 和 的靶向,我们重现了经典的小鼠NSCLC模型 。在形态、标志物表达和转录谱方面,发育中的肿瘤与源自 的肿瘤无法区分。我们证明了CRISPR在肿瘤建模中的适用性,并减少了使用传统基因工程小鼠模型的需求。此外,不仅在组成型 表达中实现了肿瘤发生,而且在野生型动物中,用两种编码CRISPR机制不同部分的离散腺相关病毒(AAV)感染肺上皮细胞也实现了肿瘤发生。虽然传统小鼠模型需要大量饲养以整合新的遗传特征以实现基因靶向,但基本的分子方法足以造成所需的基因改变 。利用CRISPR工具盒,癌症研究和建模正在迅速发展,使研究人员能够迅速开发用于转化研究的新的、临床相关的替代模型。